We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mitesco Inc (PK) | USOTC:MITI | OTCMarkets | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.29 | 0.129 | 0.44 | 0.29 | 0.129 | 0.129 | 280 | 21:02:14 |
From Jul 2019 to Jul 2024
French drug company Sanofi-Aventis SA (SNY) and U.S.-based Micromet Inc. (MITI) Thursday said they have signed an agreement to license and develop the cancer treatment BiTE antibody.
According to the agreement, Micromet will develop the treatment through Phase I trials and Sanofi will then take charge of further development and commercialization of the antibody.
Sanofi will pay Microment EUR8 million upfront, the companies said in a statement. Micromet could then receive up to EUR162 million in royalties and up to an additional EUR150 million for sales.
Company Web site: www.sanofi-aventis.com
-By Mimosa Spencer, Dow Jones Newswires; +33 01 40 17 17 73; mimosa.spencer@dowjones.com
1 Year Mitesco (PK) Chart |
1 Month Mitesco (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
